Systematic Financial Management LP Has $26.81 Million Stock Position in Healthpeak Properties, Inc. $DOC

Systematic Financial Management LP lifted its holdings in shares of Healthpeak Properties, Inc. (NYSE:DOC) by 6.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,667,139 shares of the real estate investment trust’s stock after buying an additional 104,385 shares during the period. Systematic Financial Management LP’s holdings in Healthpeak Properties were worth $26,808,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of DOC. JPMorgan Chase & Co. increased its stake in shares of Healthpeak Properties by 41.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 28,236,534 shares of the real estate investment trust’s stock worth $540,730,000 after purchasing an additional 8,212,504 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Healthpeak Properties by 694.6% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 8,016,692 shares of the real estate investment trust’s stock worth $153,520,000 after purchasing an additional 7,007,777 shares during the last quarter. Equity Investment Corp increased its stake in shares of Healthpeak Properties by 209.6% during the 3rd quarter. Equity Investment Corp now owns 5,330,948 shares of the real estate investment trust’s stock worth $102,088,000 after purchasing an additional 3,608,849 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Healthpeak Properties by 28.5% during the 3rd quarter. Bank of America Corp DE now owns 9,936,934 shares of the real estate investment trust’s stock worth $190,292,000 after purchasing an additional 2,206,222 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Healthpeak Properties by 176.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,063,569 shares of the real estate investment trust’s stock worth $58,663,000 after purchasing an additional 1,955,273 shares during the last quarter. Institutional investors and hedge funds own 93.57% of the company’s stock.

Healthpeak Properties Stock Performance

NYSE:DOC opened at $19.74 on Friday. Healthpeak Properties, Inc. has a 1 year low of $15.70 and a 1 year high of $19.91. The firm’s fifty day simple moving average is $17.49 and its 200 day simple moving average is $17.26. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $13.61 billion, a PE ratio of 61.68, a PEG ratio of 2.51 and a beta of 1.00.

Healthpeak Properties (NYSE:DOC) last posted its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. The business had revenue of $752.95 million for the quarter, compared to analyst estimates of $694.59 million. During the same period last year, the business posted $0.46 EPS. Healthpeak Properties’s revenue was up 7.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. On average, sell-side analysts anticipate that Healthpeak Properties, Inc. will post 1.75 EPS for the current year.

Healthpeak Properties Dividend Announcement

The business also recently declared a monthly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 15th will be issued a $0.1017 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a c) dividend on an annualized basis and a yield of 6.2%. Healthpeak Properties’s dividend payout ratio is 381.25%.

Insiders Place Their Bets

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the sale, the insider directly owned 7,636 shares of the company’s stock, valued at $148,520.20. This represents a 59.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.23% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Robert W. Baird increased their price target on shares of Healthpeak Properties from $19.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Scotiabank upgraded shares of Healthpeak Properties to a “hold” rating in a research note on Thursday, April 23rd. Argus lowered shares of Healthpeak Properties from a “buy” rating to a “hold” rating in a research note on Thursday, February 5th. Wall Street Zen upgraded shares of Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, UBS Group raised their target price on shares of Healthpeak Properties from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.08.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.